Listmccall9765

ders are required to confirm this hypothesis. The large interindividual variability of interaural asymmetry ratios in NB CE-Chirp and in TB at 500 Hz could be explained by the selected montage.

The asenapine transdermal system (HP-3070) is the first antipsychotic patch approved in the United States for treatment of adults with schizophrenia.

Three phase 1, open-label, randomized studies characterized the pharmacokinetic (PK) profile of HP-3070 by assessing its relative bioavailability compared with sublingual asenapine, its single-/multiple-dose PK and dose proportionality, and the effects of application site, ethnicity, and external heat on bioavailability. Two studies were conducted in healthy subjects, and 1 was conducted in adults with schizophrenia.

During single HP-3070 administration, asenapine concentrations increased gradually over approximately 12 hours and remained steady until the patch was removed 24 hours after application. Asenapine area under the curve values at HP-3070 3.8 and 7.6 mg/24 hours doses were similar to those for sublingual asenapine 5 and 10 mg twice-daily doses, respectively, whereas peak exposure (maximum observed plasma concentration) was significantly lower. Du. HP-3070 showed a predictable absorption profile with limited variability, with an area under the curve similar to that of sublingual asenapine. Based on these PK metrics, HP-3070 steadily delivers asenapine with lower peaks and troughs than sublingual administration of asenapine.

This study aimed to document the treatment trajectories and clozapine use in first-episode psychosis patients and to document the underlying reasons for using or not using clozapine in patients not achieving psychosis remission.

We conducted a retrospective chart audit of patients aged 18 to 30 years having DSM-5 diagnoses of schizophrenia spectrum psychotic disorders treated in 3 Canadian early intervention programs for psychosis. The severity of the patient's illness (using the Clinical Global Impression Severity [CGI-S] scale) and remission of psychosis were rated before and after each antipsychotic trial.

One hundred and forty-seven patients were included in the study. There were 19.7% patients exposed to clozapine after an average of 2.4 antipsychotic trials and a mean delay of 470.8 days. OD36 solubility dmso There were 75.9% patients who improved their CGI-S score (mean improvement, 2.5) after the clozapine trial and 62.1% achieved a CGI-S score ≤3. Full remission of psychosis on clozapine was achieved in 69.0% of the patients. Clozapine was successfully used for some patients with a nonadherent profile in our sample (eg, personality disorder, substance use disorder). Although the mean duration of clozapine trials during the observation period was 688.6 days, no patient discontinued clozapine because of adherence issues.

Clozapine use in these early intervention programs were at a rate consistent to what is expected from the literature and allowed a majority of patients to achieve remission of psychosis and to experience a robust improvement of severity of illness.

Clozapine use in these early intervention programs were at a rate consistent to what is expected from the literature and allowed a majority of patients to achieve remission of psychosis and to experience a robust improvement of severity of illness.

To report our early experiences with Descemet membrane endothelial keratoplasty (DMEK) in congenital hereditary endothelial dystrophy (CHED).

Retrospective analysis of medical records of eyes with CHED that underwent DMEK between January 1, 2018, and April 30, 2019, and had a minimum of 1-year follow-up.

Three eyes of 2 CHED patients (a 10-year-old girl and a 22-year-old man) were included. Both had decreased vision and hazy corneas from birth and underwent DMEK during the study period. Surgery was performed by a single surgeon and was uneventful in all 3 eyes. Within 1 month of surgery, the corneal edema cleared, and vision improved significantly. The mean decimal visual acuity improved from 0.15 ± 0.08 (baseline) to 0.33 ± 0.19 at 3 months. The mean central corneal thickness improved from 928 ± 2.3 μm (baseline) to 555.3 ± 25.8 μm at 3 months. The final visual outcome was less in 1 eye because of dense amblyopia. In all 3 eyes, a subtle stromal haze persisted even after resolution of edema. One eye had graft rejection 7 months after surgery because of discontinuation of medications, effectively managed by increasing the frequency of topical steroids.

DMEK may be a viable option in phakic eyes with CHED.

DMEK may be a viable option in phakic eyes with CHED.

To analyze the agreement of corrected intraocular pressure (IOP) values between Corvis ST (ΔIOP1) and Pentacam (ΔIOP2) in patients with keratoconus (KC), subclinical KC (sub-KC), and normal cornea.

In total, 235 eyes were divided into KC, sub-KC, and control groups. Differences in ΔIOP1 (biomechanically corrected IOP minus uncorrected IOP) and ΔIOP2 (central corneal thickness-corrected amounts of IOP) were analyzed within and among groups. Topographical and biomechanical differences were compared among the 3 groups. Factors affecting differences between ΔIOP1 and ΔIOP2 were analyzed. Agreement analysis of ΔIOP2 and ΔIOP1 was performed by Bland-Altman plots for all 3 groups.

Mean ΔIOP1 was highest in the KC group (1.23 ± 0.84 mm Hg), followed by sub-KC and control groups (all P < 0.05). Deformation amplitude ratio at 2 mm (DA-2 mm), integrated radius, stiffness parameter at first applanation, and Corvis biomechanical index values significantly differed between sub-KC and control groups. The differences between ΔIOP1 and ΔIOP2 were affected by stiffness parameter at first applanation, after adjusting for central corneal thickness and age, in all 3 groups. The lowest agreement between ΔIOP2 and ΔIOP1 was observed in the KC group (mean difference 1.90 mm Hg; 95% limit of agreement ranged from -0.2 to 3.9 mm Hg).

Among the 3 groups in this study, the KC group exhibited the worst consistency between ΔIOP2 and ΔIOP1. For the sub-KC and control groups, corrected IOP values derived by Pentacam were similar to Corvis ST. Ophthalmologists should carefully consider the mechanical properties of eyes with KC during IOP management.

Among the 3 groups in this study, the KC group exhibited the worst consistency between ΔIOP2 and ΔIOP1. For the sub-KC and control groups, corrected IOP values derived by Pentacam were similar to Corvis ST. Ophthalmologists should carefully consider the mechanical properties of eyes with KC during IOP management.